Peptide Encyclopaedia
GDF-8 (myostatin)
Also known as Myostatin.
Research / investigational listing only. This compound is not available for consumer purchase from Cellular Sequence and must not be confused with shop products.
Research / investigational compoundThis compound does not have an established approved therapeutic dosing schedule. Doses below describe those reported in published scientific research and should not be interpreted as a treatment recommendation.
At-a-glance profile
- Classification
- TGF-β superfamily ligand (protein, not a cosmetic peptide)
- Approval status
- Research only · Not approved for human use
- Research status
- Investigational / reference listing.
- Molecular formula
- Insufficient reliable evidence identified.
- Molecular weight
- Insufficient reliable evidence identified.
- Sequence
- Full myostatin protein on some lists — a muscle-inhibitory cytokine, not a ‘cutting peptide’.
- Primary biological target
- Insufficient reliable evidence identified.
- Half-life
- Insufficient reliable evidence identified.
- Routes investigated
- Insufficient reliable evidence identified.
- Human evidence level
- D — Primarily animal / preclinical evidence
What is it?
Selling myostatin as a research vial is not a hypertrophy protocol. Myostatin inhibition is a high-risk drug class. Not sold.
Mechanism of action
GDF-8 limits muscle growth; adding it would not build muscle.
Would suppress muscle if bioactive — opposite of gym marketing.
What is it being studied for?
- Myostatin biology; inhibitor drugs are a different product
Investigational findings are not proven clinical benefits unless an authority has labelled that indication.
Evidence level
Overall human evidence grade: D · Primarily animal / preclinical evidence
Human research
No registration-quality human programme as a consumer peptide product.
Preclinical research
Animal, cell and in-vitro findings are listed separately from human effects.
Scattered preclinical or analogue literature; catalogue vials are not the same as published reagents.
Doses reported in published research
This section does not provide personalised medical dosing. Values are those reported in papers or protocols. Animal mg/kg doses are not converted to human doses.
Doses reported in human studies
Insufficient reliable evidence identified.
Preclinical / animal study dosing
Insufficient reliable evidence identified.
Pharmacokinetics
Reliable human pharmacokinetic data were not identified for this encyclopaedia entry, or are limited to product information for approved presentations.
Safety
Unknown impurities, dose error, and infection risk dominate grey-market injectables.
Unknowns. Absence of a published harm signal is not evidence of safety.
Contraindications. Not for human use. Not for compounding outside a licensed pharmacy and lawful prescription.
Regulatory status
Not an approved finished medicine in typical grey-market vial form.
Cellular Sequence does not sell this as a vial, tablet, oil, or injectable. Educational encyclopaedia listing only.
Citations
[1] Encyclopaedia note
Encyclopaedia note
For educational and research reference only. This page summarises published scientific literature and does not constitute medical advice, prescribing information or a recommendation to use an investigational compound. Research doses shown describe doses reported in published studies and are not personalised dosing instructions.
Last reviewed 2026-09-13. Research areas: Performance · Compare peptides